EMPOWERING DENDRITIC CELLS

Amphera B.V., an advanced-clinical-stage biotechnology company, develops dendritic cell therapies for the treatment of cancer. Our lead indication is mesothelioma, a cancer of the lining of the lungs. MesoPher is autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour Associated Antigens. Several clinical studies with our lead product candidate MesoPher are ongoing.

MEET US AT

25-27 March 2019
Bio Europe Spring – Vienna

3-6 June 2019
Bio International
Convention – Philadelphia

10-13 November 2019
Bio Europe – Hamburg